What is ImmunityBio, Inc.'s remainder of 2026?

ImmunityBio, Inc. (IBRX) reported remainder of 2026 of $3.21M in Q1 2026.

How has ImmunityBio, Inc.'s remainder of 2026 changed year-over-year?

ImmunityBio, Inc.'s remainder of 2026 increased by 109.5% year-over-year, from $1.53M to $3.21M.

ImmunityBio, Inc. IBRX Remainder of 2026

Remainder of 2026 at other companies

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s remainder of 2026.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s remainder of 2026?: ImmunityBio, Inc. (IBRX) reported remainder of 2026 of $3.21M in Q1 2026.
How has ImmunityBio, Inc.'s remainder of 2026 changed year-over-year?: ImmunityBio, Inc.'s remainder of 2026 increased by 109.5% year-over-year, from $1.53M to $3.21M.